跳到正文
MarketHOT
English
摘要
SEC · EDGAR 财务披露·· 12 天前AI 评分16

Tiziana Life Sciences 提交 6-K/A 修正文件,将原报告纳入注册声明

6-K/A - Tiziana Life Sciences Ltd (0001723069) (Filer)

AI 导读

Tiziana Life Sciences 于 11 月 2 日提交 6-K/A 修正文件,修订其 10 月 16 日提交的 6-K 报告。修正内容仅为将原报告及其附件 99.1 以引用方式纳入公司 Form F-3 和 Form S-8 注册声明。

正文

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K/A

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

November 2026

Commission File Number:  001-38723

Tiziana Life Sciences LTD

(Exact Name of Registrant as Specified in Its Charter)

9th Floor

107 Cheapside

London

EC2V 6DN

(Address of registrant’s principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K/A

This Amendment No. 1 on Form 6-K/A (this “Amendment”) amends the Report on Form 6-K furnished by Tiziana Life Sciences LTD to the Securities and Exchange Commission (the “SEC”) on October 16, 2026 (the “Original Form 6-K”) solely to provide that the information contained in the Original Form 6-K, including Exhibit 99.1 thereto, is incorporated by reference into the Company’s Registration Statement on Form F-3 (Reg. No. 333-286064) and Form S-8 (Reg. No. 333-293620).

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

  TIZIANA LIFE SCIENCES LTD
       
Date: November 2, 2026 By: /s/ Keeren Shah
    Name: Keeren Shah
    Title: Chief Financial Officer

2

来源:SEC EDGAR · 本站存档